These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34401911)

  • 1. Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study.
    Rosenstein MD; de Visser AW; Visser LG; Roukens AHE
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34401911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of post-vaccination humoral immunity against yellow fever in children.
    de Noronha TG; de Lourdes de Sousa Maia M; Geraldo Leite Ribeiro J; Campos Lemos JA; Maria Barbosa de Lima S; Martins-Filho OA; Campi-Azevedo AC; da Silva Freire M; de Menezes Martins R; Bastos Camacho LA;
    Vaccine; 2019 Nov; 37(48):7147-7154. PubMed ID: 31590934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.
    Roukens AH; Soonawala D; Joosten SA; de Visser AW; Jiang X; Dirksen K; de Gruijter M; van Dissel JT; Bredenbeek PJ; Visser LG
    PLoS One; 2011; 6(12):e27753. PubMed ID: 22163273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults.
    Miyaji KT; Avelino-Silva VI; Simões M; Freire MD; Medeiros CR; Braga PE; Neves MA; Lopes MH; Kallas EG; Sartori AM
    Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e2. PubMed ID: 28380113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
    Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
    N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.
    Martin C; Florence E; Domingo C; Delforge M; De Wit S; Dauby N
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 35285913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study.
    Domingo C; Fraissinet J; Ansah PO; Kelly C; Bhat N; Sow SO; Mejía JE
    Lancet Infect Dis; 2019 Dec; 19(12):1363-1370. PubMed ID: 31543249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study.
    Doshi RH; Mukadi PK; Casey RM; Kizito GM; Gao H; Nguete U B; Laven J; Sabi L; Kaba DK; Muyembe-Tamfum JJ; Hyde TB; Ahuka-Mundeke S; Staples JE
    Lancet Infect Dis; 2024 Jun; 24(6):611-618. PubMed ID: 38335976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of post-vaccination immunity against yellow fever in adults.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2014 Sep; 32(39):4977-84. PubMed ID: 25090646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
    Cristina Martini Rodrigues C; Caroline Ribeiro Sales A; Marli Christovam Sartori A; de Souza Azevedo A; Maria Barbosa de Lima S; de Melo Picone C; Keiko Sato P; Nazareth Lara A; Takesaki Miyaji K; Sérgio Azevedo L; Caldin B; Camera Pierrotti L; Heloisa Lopes M
    Vaccine; 2024 Apr; 42(11):2729-2732. PubMed ID: 38514353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2019 Aug; 37(35):5129-5135. PubMed ID: 31171393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.
    Gibney KB; Edupuganti S; Panella AJ; Kosoy OI; Delorey MJ; Lanciotti RS; Mulligan MJ; Fischer M; Staples JE
    Am J Trop Med Hyg; 2012 Dec; 87(6):1112-5. PubMed ID: 23109371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
    Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
    Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
    Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
    Front Immunol; 2019; 10():2192. PubMed ID: 31616412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
    Front Immunol; 2020; 11():577751. PubMed ID: 33133096
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
    Roukens AHE; van Halem K; de Visser AW; Visser LG
    Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination.
    Wieten RW; Jonker EF; van Leeuwen EM; Remmerswaal EB; Ten Berge IJ; de Visser AW; van Genderen PJ; Goorhuis A; Visser LG; Grobusch MP; de Bree GJ
    PLoS One; 2016; 11(3):e0149871. PubMed ID: 26977808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.